Compare FTRE & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTRE | TLRY |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 829.3M | 688.9M |
| IPO Year | 2023 | 2018 |
| Metric | FTRE | TLRY |
|---|---|---|
| Price | $13.67 | $5.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $14.06 | ★ $72.33 |
| AVG Volume (30 Days) | 1.5M | ★ 7.0M |
| Earning Date | 05-05-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,723,400,000.00 | N/A |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | $3.09 | $19.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $3.97 | $0.36 |
| 52 Week High | $18.67 | $15.70 |
| Indicator | FTRE | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 59.26 | 32.23 |
| Support Level | $8.85 | $1.12 |
| Resistance Level | $18.26 | $7.01 |
| Average True Range (ATR) | 0.82 | 0.25 |
| MACD | 0.07 | -0.07 |
| Stochastic Oscillator | 54.77 | 4.99 |
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.